
Akouos AKUS
Quarterly report 2022-Q3
added 11-14-2022
Akouos General and Administrative Expenses 2011-2026 | AKUS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Akouos
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 22.2 M | 14.6 M | 3.41 M | 1.78 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.2 M | 1.78 M | 10.5 M |
Quarterly General and Administrative Expenses Akouos
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 6.27 M | 6.68 M | 6.65 M | - | 5.51 M | 5.66 M | 4.89 M | - | 4.48 M | 2.66 M | 2.5 M | - | 887 K | 749 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.68 M | 749 K | 4.27 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Assembly Biosciences
ASMB
|
19.6 M | $ 28.46 | 3.45 % | $ 319 M | ||
|
Ascendis Pharma A/S
ASND
|
160 M | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Axsome Therapeutics
AXSM
|
63.3 M | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | ||
|
Pharming Group N.V.
PHAR
|
11.7 M | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.37 | -4.2 % | $ 350 M | ||
|
Kamada Ltd.
KMDA
|
12.6 M | $ 8.5 | -1.39 % | $ 260 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Benitec Biopharma
BNTC
|
6.97 M | $ 10.98 | -4.52 % | $ 452 M | ||
|
Inventiva S.A.
IVA
|
11.2 M | $ 5.78 | -4.3 % | $ 138 M | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Compugen Ltd.
CGEN
|
10.9 M | $ 2.09 | -0.95 % | $ 195 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
286 K | $ 1.21 | -3.97 % | $ 71.5 M | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
PainReform Ltd.
PRFX
|
124 K | $ 2.28 | -0.44 % | $ 1.03 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
Foghorn Therapeutics
FHTX
|
27.6 M | $ 5.0 | 2.25 % | $ 315 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
AbCellera Biologics
ABCL
|
83.2 M | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Curis
CRIS
|
16.8 M | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | ||
|
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
101 M | $ 1.52 | -5.59 % | $ 178 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
99.3 M | $ 7.7 | -5.87 % | $ 1.29 B | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Cellectis S.A.
CLLS
|
37.9 M | $ 3.34 | -4.02 % | $ 116 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.24 | -2.97 % | $ 704 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Cardiff Oncology
CRDF
|
14.2 M | $ 1.8 | -1.1 % | $ 120 M | ||
|
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | ||
|
Cabaletta Bio
CABA
|
19.2 M | $ 2.94 | -3.29 % | $ 3.43 M | ||
|
Iterum Therapeutics
ITRM
|
7.98 M | $ 0.16 | -5.45 % | $ 3.15 M | ||
|
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M |